Physiometrix submits anaesthesia monitor to FDA:
This article was originally published in Clinica
Physiometrix has submitted a 510(k) marketing application to the US FDA for its PSA 5000 next generation device for monitoring and managing a patient's level of consciousness while under anaesthesia. The PSA 5000 is more powerful, cost effective and ergonomic than its predecessor, the PSA 4000, said the North Billerica, Massachusetts company. "We believe this next generation technology, with several new features, will further differentiate us from our competition," added John Williams, the firm's president and CEO.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.